Literature DB >> 26866291

Integrated care for Down syndrome.

Ni-Chung Lee1,2, Yin-Hsiu Chien1,2, Wuh-Liang Hwu1,2.   

Abstract

Down syndrome (DS), caused by an extra copy of chromosome 21 (trisomy 21), is the most intensively studied human aneuploidy condition. It is the leading cause of intellectual disability and birth defects. Although most prenatally diagnosed DS fetuses are aborted in Taiwan, there are still some infants with DS who are diagnosed after birth. In addition to intellectual disability, people with DS face systemic problems that include short stature, dysmorphism, congenital heart disease, congenital anomalies of gastrointestinal and genitourinary tracts, abnormal endocrine function, leukemia and leukemoid reactions. To provide better care for people with DS in Taiwan, we began the DS multi-disciplinary clinic that has opened once per month since November 2013. The multi-disciplinary clinic consists of several subspecialists who provide care for DS people. To date, approximately 200 patients have used the clinic. The average number of patients who use the clinic per month is 27±6 with a mean patient age of 16±12 years old (range 0.3-53 years). The average number of patients per specialist on each clinic day is 5.2±4.9 (range 0.5-20.9 patients). We focus on early detection and prevention of medical and developmental issues associated with DS. This coordinated approach allows DS patients and family to have more comprehensive care.
© 2016 Japanese Teratology Society.

Entities:  

Keywords:  Down syndrome; integrated care; multi-disciplinary clinic

Mesh:

Year:  2016        PMID: 26866291     DOI: 10.1111/cga.12159

Source DB:  PubMed          Journal:  Congenit Anom (Kyoto)        ISSN: 0914-3505            Impact factor:   1.409


  1 in total

1.  Under-reporting of major birth defects in Northwest Russia: a registry-based study.

Authors:  Anton A Kovalenko; Tormod Brenn; Jon Øyvind Odland; Evert Nieboer; Alexandra Krettek; Erik Eik Anda
Journal:  Int J Circumpolar Health       Date:  2017       Impact factor: 1.228

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.